Breast Cancer Index (BCI) is a tumor gene-expression test used in selected hormone receptor-positive, HER2-negative early breast cancers to refine two questions that become especially important after several years of endocrine therapy: how much risk of distant recurrence remains, and whether extending endocrine therapy beyond about five years is likely to provide meaningful benefit. The test is performed on stored tumor tissue, not on blood, and it combines gene-expression information related to tumor proliferation and estrogen signaling. BCI reports prognostic information about recurrence risk and a separate predictive H/I result for extended endocrine therapy benefit. Those outputs should not be collapsed into one “good” or “bad” score. BCI also does not replace tumor stage, nodal status, grade, age, treatment tolerance, bone health, or patient preferences. Its main value is helping a clinician and patient make a more individualized decision when the tradeoff between additional endocrine therapy and its side effects is genuinely uncertain.
- Breast Cancer Index is performed on previously removed tumor tissue; it does not require a new blood draw.
- BCI is mainly used in hormone receptor-positive, HER2-negative early breast cancer when considering endocrine therapy duration.
- The prognostic component estimates distant-recurrence risk, including risk during years 5–10 after diagnosis in validated groups.
- The BCI H/I result is reported as High or Low and is intended to predict likelihood of benefit from extended endocrine therapy.
- A BCI result should not be used by itself to start, stop, or extend hormone therapy without considering nodes, tumor size, prior therapy, side effects, and competing health risks.
Table of Contents
- What Breast Cancer Index Measures
- Who May Be Considered for BCI Testing
- How the Test Is Performed and What the Report Shows
- How to Interpret the Late Recurrence Risk
- What the H/I Result Means for Extended Endocrine Therapy
- Weighing Extended Therapy Benefits Against Side Effects
- Questions to Ask Before Acting on a BCI Result
What Breast Cancer Index Measures
Breast Cancer Index is a gene-expression assay for formalin-fixed, paraffin-embedded breast tumor tissue. It evaluates two biologic components. One is a molecular grade index that captures expression of proliferation-related genes. The other is the HOXB13/IL17BR expression ratio, usually shortened to H/I, which reflects estrogen-signaling biology and has been studied as a marker of endocrine sensitivity and resistance.
The assay integrates these signals into prognostic information about distant recurrence. In its validated clinical use, the most distinctive question is late recurrence—cancer returning at a distant site after the first five years. Hormone receptor-positive breast cancer differs from many cancers because recurrence risk can persist for a long time, even after a patient has completed five years of endocrine therapy without evidence of disease.
BCI also provides a predictive result based on H/I that is used to estimate whether extended endocrine therapy is likely to reduce recurrence risk. “Predictive” has a specific meaning here: it refers to evidence that treatment effect differs according to the biomarker. It does not mean BCI can predict with certainty what will happen to one person.
This dual role is why BCI can be confusing. A person can have relatively low late-recurrence risk but an H/I result suggesting potential treatment benefit, or a higher prognostic risk with an H/I result that does not show clear evidence of extended-therapy benefit. The result must be read as two related but distinct pieces of information rather than one pass/fail label.
BCI is different from Oncotype DX, which is commonly used earlier in the treatment course to help guide chemotherapy decisions in defined populations. It is also different from EndoPredict, another prognostic gene-expression assay used in early hormone receptor-positive/HER2-negative disease.
Who May Be Considered for BCI Testing
BCI is most relevant for people with early-stage, hormone receptor-positive, HER2-negative invasive breast cancer who have already completed or are approaching completion of an initial course of adjuvant endocrine therapy. The clinical question is usually whether to stop around five years or continue for additional years.
ASCO’s biomarker guideline supports use of BCI in selected postmenopausal patients with ER-positive/HER2-negative disease who are node-negative or have one to three positive lymph nodes, and it specifically recognizes BCI as a test that may be offered to patients with zero to three positive nodes who have received five years of endocrine therapy without recurrence to help guide decisions about extended therapy. Eligibility still depends on the exact clinical scenario.
The test is less useful when the decision is already obvious for reasons unrelated to tumor biology. A patient who has had severe, persistent toxicity from endocrine therapy may decide not to continue regardless of BCI. At the other extreme, a person with very high clinical risk and excellent treatment tolerance may already have a strong reason to continue therapy. BCI adds the most value when reasonable clinicians and patients could choose either direction.
Premenopausal status, prior ovarian suppression, type of endocrine therapy, nodal burden, and treatment history can affect how evidence applies. Many pivotal extended-therapy data sets were dominated by postmenopausal women. A clinician should therefore confirm that the patient resembles the population in which the assay and treatment interaction were studied.
BCI is not a general screening test, a hereditary genetic test, or a test for metastatic disease monitoring. It analyzes the original tumor’s RNA. A germline BRCA1/2 test answers a completely different question about inherited cancer susceptibility.
How the Test Is Performed and What the Report Shows
BCI generally uses archived tissue from the original breast surgery or biopsy. The pathology laboratory identifies an appropriate block containing invasive tumor, and the testing laboratory extracts RNA from the formalin-fixed tissue. Because the assay is performed on stored tissue, a new biopsy is usually unnecessary if adequate material remains available.
The report typically separates prognostic and predictive information. The prognostic portion can provide an individualized estimate of distant recurrence risk over a specified period, including late distant recurrence in years 5–10 in applicable patients. The predictive portion reports BCI (H/I) as High or Low for likelihood of benefit from extended endocrine therapy.
It is important to read the time horizon printed on the report. A 5–10-year late-recurrence estimate is not the same as a lifetime risk, and it is not the same as the chance of any local or distant event. Similarly, a percentage on the report should not be assumed to include the effect of every treatment a patient received unless the report and validation data specify that context.
The H/I High/Low call is not a percentage of estrogen receptors and should not be confused with the ER immunohistochemistry result. ER IHC identifies hormone-receptor expression in tumor cells; BCI H/I measures a gene-expression ratio associated with endocrine biology and treatment interaction.
If the report contains unfamiliar terms, ask the oncologist to point to the line that answers each question: “What is my estimated late distant-recurrence risk?” and “Does the H/I result suggest benefit from extending endocrine therapy?” Keeping those questions separate prevents a common misreading of the test.
How to Interpret the Late Recurrence Risk
Hormone receptor-positive breast cancer can recur many years after initial treatment. Clinical factors such as tumor size, grade, nodal involvement, age, and the depth of hormone-receptor expression already provide important information about that risk. BCI adds tumor gene-expression data intended to refine the estimate.
A lower BCI prognostic risk means the tumor’s molecular profile and the assay’s validated model are associated with a lower probability of distant recurrence over the reported interval. It does not mean the risk is zero. A higher result means residual risk is more substantial, not that recurrence is inevitable. The estimate is best treated as one input in a broader risk conversation.
The distinction between early and late recurrence is useful because treatment decisions change over time. At diagnosis, the key decisions may involve chemotherapy, radiation, and the initial endocrine regimen. At year five, the question is no longer whether endocrine therapy works in principle; it is whether the additional absolute benefit of more therapy is large enough to justify continued exposure to side effects.
Clinical risk and genomic risk can disagree. A small node-negative tumor can still have higher molecular risk, while a larger or node-positive tumor can sometimes have a lower molecular signal than expected. Discordance does not mean one test is “wrong.” It means the tools measure different aspects of risk. The patient’s final decision should consider both.
The BCI risk estimate should also be viewed alongside adherence. Five calendar years since diagnosis are not identical to five years of consistently taking prescribed endocrine therapy. Long treatment gaps, early switches, or poor tolerance may change the clinical context and deserve discussion before using any late-recurrence estimate to decide what comes next.
What the H/I Result Means for Extended Endocrine Therapy
The BCI H/I result is intended to predict whether continuing endocrine therapy beyond the initial period is likely to provide benefit. Several prospective-retrospective analyses of randomized trials have reported greater benefit from extended therapy in H/I-High groups than in H/I-Low groups. That evidence is the basis for BCI’s role in endocrine-duration decisions.
However, the evidence is not perfectly uniform. In the 2024 translational analysis of the NSABP B-42 trial, the primary analysis did not show a statistically significant interaction between H/I status and extended letrozole for recurrence-free interval. The study was underpowered for that endpoint. Time-dependent analyses suggested a later reduction in distant recurrence among H/I-High patients after four years of extended therapy, but not among H/I-Low patients. This mixed result is a useful reminder that a predictive biomarker should not be presented as infallible.
The 2022 final Trans-aTTom analysis also illustrates the importance of subgroup context. In the node-positive subset, H/I-High patients had a substantial absolute benefit from extended tamoxifen, while H/I-Low patients did not show benefit. The overall study population, however, did not show a significant improvement in recurrence-free interval, partly because of low event rates and limited power in node-negative patients.
A 2023 systematic review found that available studies generally supported BCI as predictive of extended endocrine therapy response, while emphasizing that the evidence base was small and populations were predominantly postmenopausal and non-Hispanic White. That limitation matters when counseling an individual patient.
The practical interpretation is therefore: H/I can help tilt a decision, but it does not override treatment toxicity, menopausal status, bone density, cardiovascular risk, uterine risk with tamoxifen, recurrence risk, or patient preference.
Weighing Extended Therapy Benefits Against Side Effects
Extended endocrine therapy can reduce recurrence risk for some patients, but the average absolute benefit is often modest. The decision therefore depends on both the chance of recurrence and the burden of treatment. Aromatase inhibitors can contribute to joint pain, bone loss, fractures, vaginal symptoms, and sexual side effects. Tamoxifen can cause hot flashes and carries uncommon but important risks such as venous thromboembolism and endometrial cancer, with risk varying by age and individual factors.
A genomic result is most useful when translated into absolute benefit. A relative risk reduction can sound large while producing only a small absolute difference if baseline late-recurrence risk is low. Conversely, a modest relative effect can matter more when baseline risk is high. Ask the oncologist to explain both the baseline risk and the expected range of benefit from additional therapy.
Bone health deserves special attention for people continuing an aromatase inhibitor. Bone-density testing, adequate calcium and vitamin D intake when appropriate, weight-bearing exercise, fall prevention, and bone-protective treatment may be considered according to standard care. Symptoms should also be managed rather than accepted as the unavoidable price of treatment; changing the endocrine agent or supportive-care plan can sometimes improve adherence.
The decision can be revisited. Choosing to extend therapy does not mean a patient must tolerate severe toxicity for years without reassessment. Likewise, choosing to stop at five years should follow a deliberate review of clinical risk and preferences rather than assuming that five years is universally sufficient.
BCI helps make this tradeoff more personalized, but the ultimate decision remains a shared one because the value of a given absolute benefit differs from person to person.
Questions to Ask Before Acting on a BCI Result
Start by confirming the indication. Ask whether the tumor is within a population for which BCI has clinical evidence: hormone receptor-positive, HER2-negative early breast cancer, with nodal status and prior treatment that fit current guidance. If the test was ordered for a different purpose, ask what evidence supports that use.
Next, ask the oncologist to separate the report into its two outputs. “What is my prognostic risk of late distant recurrence?” and “Is my H/I result High or Low for extended endocrine benefit?” are clearer than asking whether the BCI is simply “good” or “bad.”
Ask how the result compares with clinical risk. Tumor size, number of involved nodes, grade, age, and treatment history remain important. A result that conflicts with those factors deserves explanation, not automatic priority.
Then discuss the treatment alternatives in concrete terms: stop endocrine therapy now, continue the current drug, switch endocrine agents, or continue for a defined additional duration. For each option, review side effects, bone and cardiovascular health, quality of life, and the estimated absolute recurrence reduction.
Finally, recognize what BCI cannot answer. It does not detect current recurrence, monitor response, determine hereditary risk, or guarantee that extended therapy will or will not work. If symptoms suggest recurrence, evaluation should proceed clinically regardless of a prior low BCI result.
A well-used BCI test narrows uncertainty. It should leave the patient with a clearer treatment choice and a clearer understanding of the tradeoff, not simply another molecular label.
What Breast Cancer Index cannot decide by itself
BCI can add evidence to an extended-endocrine-therapy decision, but it does not replace the rest of the risk assessment. A patient with substantial nodal involvement, a large high-grade tumor, major treatment toxicity, osteoporosis, thromboembolic risk, or strong preferences may reach a different decision from another patient with the same BCI result. The assay informs one part of the balance: residual recurrence risk and, through the H/I component, evidence about extended endocrine benefit in validated populations.
The test also does not tell whether a person is currently cancer-free. It is performed on the original tumor tissue and estimates future risk; it is not a surveillance blood test and does not detect minimal residual disease. A “low” result should not be interpreted as zero chance of late recurrence, and a “high” result does not mean recurrence is inevitable.
Treatment benefit must be separated from side-effect burden. Additional years of an aromatase inhibitor can worsen bone loss, joint symptoms, and other quality-of-life problems, while tamoxifen has a different risk profile that includes thromboembolic and uterine effects. Those harms depend on age, menopausal status, prior therapy, medical history, and the specific drug under consideration.
A practical discussion therefore combines the BCI report with nodal status, tumor size and grade, years already completed on endocrine therapy, prior tolerance, bone health, competing health risks, and the patient’s priorities. The most useful question is not “Is my BCI good or bad?” but “How much additional recurrence-risk reduction might extended therapy offer me, and is that benefit worth the additional treatment burden in my situation?”
References
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update 2022 (Guideline)
- Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial 2024 (RCT)
- Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis 2023 (Systematic Review)
- Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study 2022 (RCT)
- Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2024 (Guideline)
Disclaimer
This article provides general information about Breast Cancer Index and extended endocrine therapy. A BCI result should be interpreted by the treating oncology team in the context of tumor stage, nodal status, prior treatment, side effects, other health conditions, and current guidelines.
